A scintigraphy study of budesonide/ glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.

We worked in partnership with Cardiff Scintigraphics Ltd to deliver this study to demonstrate effective lung deposition of a novel triple combination pressurised metered dose inhaler (pMDI) in COPD patient population.

A Phase I, Single-Dose, Gamma Scintigraphy Study to Assess the Pulmonary Deposition of Technetium-99m Radiolabelled Budesonide, Glycopyrronium and Formoterol Fumarate MDI Following a Maximal Breath-Hold of up to 10 seconds in Patients with Moderate to Severe/Very Severe Chronic Obstructive Pulmonary Disease (COPD).

Back to Clinical Trial Publications Archive